Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955644 | 0.77 | CYP3A4 (0.58) | CYP3A4ALOX15POLBACHEALDH1A1 | |
| SCHEMBL29936543 | 0.77 | CYP3A4 (0.58) | CYP3A4ALOX15POLBACHEALDH1A1 | |
| SCHEMBL25371015 | 0.76 | CYP3A4 (0.67) | CYP3A4ALOX15POLBMAPTPDE4A | |
| SCHEMBL4943745 | 0.69 | CYP3A4 (0.50) | CYP3A4ALOX15POLBACHEALDH1A1 | |
| SCHEMBL4942498 | 0.69 | POLB (0.50) | CYP3A4ALOX15POLBACHEALDH1A1 | |
| SCHEMBL9727047 | 0.69 | IMPDH2 (0.48) | MAPTMAOA | |
| SCHEMBL25845085 | 0.69 | POLB (0.44) | CYP3A4ALOX15POLBACHEALDH1A1 | |
| SCHEMBL10430644 | 0.69 | POLB (0.48) | CYP3A4ALOX15POLBALDH1A1CYP1A2 | |
| SCHEMBL20362610 | 0.68 | MAPT (0.47) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10429774 | 0.68 | CYP3A4 (0.49) | CYP3A4ALOX15POLBMAPTPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759549-B2 | Compound extracted from Antrodia cinnamomea and pharmaceutical composition comprising the same | Yu, Chieh-Chou (TW) | 2014-06-24 | — | — | US | disclosed |
| US-20120029069-A1 | Compound Extracted From Antrodia Cinnamomea and Pharmaceutical composition comprising the same | Yu, Chieh-Chou (TW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029069-A1 | Compound Extracted From Antrodia Cinnamomea and Pharmaceutical composition comprising the same | Yu, Chieh-Chou (TW) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029069-A1 | Compound Extracted From Antrodia Cinnamomea and Pharmaceutical composition comprising the same | ACAD11, CYP51A1, SLC47A1 | CYP3A4 273/4885ALOX15 1305/4885POLB 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.